Vantage logo

Pre-Esmo jitters for Roche

Discontinuations and an unusual revelation about Tecentriq’s breast cancer data dominated the R&D part of the company’s third-quarter results call.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.